Stem Cell Transplantation for Stiff Person Syndrome (SPS)
Status:
Terminated
Trial end date:
2019-08-30
Target enrollment:
Participant gender:
Summary
Non-myeloablative regimens (as the investigators use herein) are designed to maximally
suppress the immune system without destruction of the bone marrow stem cell compartment.
When using a non-myeloablative regimen recovery occurs without infusion of stem cells and the
stem cells are autologous. While not necessary for recovery, stem cell infusion may shorten
the interval of neutropenia and attendant complications. Thus in reality there is no
transplant only an autologous supportive blood product.
Based on our encouraging results of non-myeloablative hematopoietic stem cell
transplantation, for patients with multiple sclerosis and chronic inflammatory demyelinating
polyneuropathy, the investigators will investigate the role of non-myeloablative
hematopoietic stem cell transplantation for patients with SPS who require assistance to
ambulate.